Status
Active, not recruiting
Phase
Not applicable
Enrollment
71
Locations
1
Results
Not posted
Publications
0
Study summary
Vasopressin is a key regulator of water and vascular homeostasis, acting through V2 receptors to control renal water reabsorption and through V1a receptors to influence vascular tone. Copeptin, a stable surrogate marker of vasopressin release, provides a reliable measure of vasopressin activity. In hemodialysis, where ultrafiltration and osmotic shifts challenge fluid balance, the contribution of vasopressin to intradialytic blood pressure regulation remains uncertain. Elevated copeptin levels in dialysis patients have been associated with interdialytic weight gain and adverse cardiovascular outcomes. This study (CODIALHYP) tests the hypothesis that vasopressin activity, assessed through copeptin levels, is associated with intradialytic hypertension. The primary objective is to evaluate the relationship between copeptin concentrations and blood pressure changes during hemodialysis. Secondary objectives include assessing whether vasopressin's antidiuretic effect is preserved in hemodialysis patients and exploring the contribution of other hormonal pathways involved in fluid and vascular regulation.
This study investigates the role of vasopressin activity, assessed through copeptin levels, in the hemodynamic changes occurring during hemodialysis. Vasopressin is involved in both water homeostasis and vascular regulation, yet its contribution to intradialytic blood pressure variations remains insufficiently characterized. Hemodialysis induces rapid shifts in osmotic gradients and extracellular volume, creating conditions in which vasopressinmediated mechanisms may influence vascular tone and fluid balance. The research is based on a retrospective observational design involving chronic hemodialysis patients. Clinical records were reviewed to collect blood pressure measurements obtained before, during, and after dialysis sessions, as well as laboratory data including copeptin, plasma osmolality, cortisol, and aldosterone. When residual diuresis was present, urinary volume and osmolality were documented. Additional information related to dry weight, ultrafiltration parameters, and routine markers of fluid balance was extracted from standard clinical evaluations. These data provide a framework for examining the association between vasopressin activity and intradialytic hypertension, and for exploring the contribution of other hormonal pathways involved in fluid and vascular regulation.
Interventions
DIAGNOSTIC_TEST
Copeptin concentration will be measured from routine plasma samples, and blood pressure values will be recorded before, during, and after hemodialysis sessions using standard clinical monitoring. The primary outcome is the association between copeptin levels and intradialytic blood pressure variation.
Timeline
First posted
Feb 27, 2026
Study start
Dec 22, 2025
Primary completion
Mar 1, 2026
Study completion
Mar 1, 2026
Results posted
Not reported
Registry updated
Feb 27, 2026
Outcomes
Copeptin Concentration Measured in Plasma Samples and Intradialytic Blood Pressure Variation
Time frame · At baseline (M0) and at 3 months (M3), with copeptin measured at dialysis initiation (prehemodialysis) without additional blood sampling.
Copeptin concentration will be measured from routine plasma samples, and blood pressure values will be recorded before, during, and after hemodialysis sessions using standard clinical monitoring. The primary outcome is the correlation between copeptin levels and intradialytic blood pressure variation.
Plasma Osmolality
Time frame · Baseline (M0)
Plasma osmolality (mOsm/kg) will be obtained from routine predialysis laboratory measurements. These measurements will be used to evaluate whether the antidiuretic effect of vasopressin is preserved in hemodialysis patients.
Copeptin level
Time frame · Baseline (M0)
Copeptin levels (pmol/L) will be obtained from routine predialysis laboratory measurements.
Serum Cortisol and Aldosterone Concentrations
Time frame · Baseline (M0)
Serum cortisol and aldosterone concentrations will be measured from routine predialysis blood samples collected as part of standard care. These hormonal markers will be used to explore additional mechanisms potentially involved in intradialytic hypertension.
Urinary Osmolality
Time frame · Baseline (M0)
Urinary volume and urine osmolality will be collected from standard clinical assessments in patients with residual diuresis. These measurements will be used to evaluate whether the antidiuretic effect of vasopressin is preserved in hemodialysis patients.
Eligibility
Inclusion Criteria: * Adult patients (≥18 years old). * Undergoing chronic hemodialysis treatment \> 3 months. * Availability of routine predialysis blood samples for copeptin and biochemical measurements. * Availability of blood pressure recordings before, during, and after hemodialysis sessions. No exclusion criteria if inclusion criteria is filled
Study locations
France. Showing up to 24 locations stored in the fast local snapshot.
CHRU de Nancy
Vandœuvre-lès-Nancy, France
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
First Affiliated Hospital, Sun Yat-Sen University · Liver Neoplasms · Postoperative Complications
Not applicable
Completed
161
2026-07
Montefiore Medical Center · Cervical Preparation
Phase 1
Recruiting
94
2026-07
Elizabeth Austen Lawson · Vasopressin Deficiency
Phase 1
Recruiting
40
2026-07
Massachusetts General Hospital · Arginine Vasopressin Deficiency · Oxytocin Deficiency
Early Phase 1
Recruiting
20
2026-07
Zhaoyun Zhang · Craniopharyngiomas · Pituitary Macroadenoma
Phase 4
Enrolling by invitation
152
2026-07
Otsuka Pharmaceutical Development & Commercialization, Inc. · Hyponatremias · Water Intoxication
Phase 3
Completed
205
2026-07
Otsuka Pharmaceutical Development & Commercialization, Inc. · Hyponatremia
Phase 3
Completed
243
2026-07
Beijing Friendship Hospital · Kidney Transplant · Delayed Graft Function
Not applicable
Active, not recruiting
150
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.